When we administered glycyrrhizin or other HMGB1-neutralizing antibodies to desmoplasma-resistant prostate cancer cells that had developed resistance to paclitaxel, and then treated the cells again with paclitaxel, their sensitivity to paclitaxel was significantly restored (76). Here, HMGB1 is linked to prostate cancer.